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In Reply We thank Dr Macerollo for the interesting commen-
taryonour article.1Mutations in theglucocerebrosidase (GBA)
gene are widely recognized to be an important and common
genetic risk factor for Parkinson disease (PD),2 and they are
found in British patients with PD at a higher frequency than
any other known PD-associated gene.3
In 2012, we continued the clinical evaluation of a unique
cohort ofGBAmutation–positive individuals for the earlypro-
dromal featuresofPD.1Whatwasperhaps surprisingabout this
nonparkinsonian GBA–positive cohort at the initial assess-
ment in 2010 was a significant difference from control indi-
viduals evenat thebaseline evaluation.4At baseline,GBAmu-
tation–positive individuals demonstrated hyposmia and
cognitive impairment.4 Importantly, we found that olfaction
and cognition remained significantly lower inGBAmutation–
positive individuals compared with control individuals at
2 years’ follow-up.1 We further identified a significant dete-
rioration across clinical markers in GBA mutation–positive
individuals, consistent with the prodrome of PD. Within this
group, 10% appeared to be progressing at amore rapid rate. It
is interesting to compare our results, which identified 10% of
GBAmutation–positive individuals developing parkinsonian
motor features, with the reported estimate that 10% of pa-
tients with PD carry a mutation in GBA.2
Improved insight into possible disease mechanisms lays
thebasis for thedevelopmentofnewtherapies to slowthe rate
of progression or stop thedisease process.5 Thus, it is impera-
tive to develop an early biomarker set to identify individuals
at greatest risk for thedevelopment of PD. In this study,we at-
tempted to identify patients likely to develop PD through the
use of early clinical markers.1 This study cohort would be an
idealpopulation tostudyaneuroprotectivestrategyordisease-
modifying therapy.
AsobservedbyDrMacerollo, ourdata favor a linkbetween
theGBAmutation and a higher frequency of nonmotor symp-
toms and rate of clinical progression. Our work1 and those of
others6,7may suggest that theGBAmutation represents a poor
prognosticmarker for an individualwhodevelopsPD.Theevi-
dencefromlongitudinalstudiesdemonstratesthatpatientswith
GBA-associatedPDshowamorerapiddiseaseprogressiondomi-
natedbyacceleratedmotor impairmentwithgreater riskforpro-
gression toHoehnandYahrScale stage37 andagreaterprepon-
derance to dementia or cognitive decline.6
Dr Macerollo asks about the specific alterations that lead
to developing PD in a group of GBA mutation–positive indi-
viduals. We can only hypothesize that other genetic or possi-
bly environmental factorsmay be of relevance here. Study of
GBA mutation–positive individuals who do not go on to de-
velopPDcouldprovide insight into factors thatmayaffordpro-
tection from PD.
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